First patient dosed in unique biomarker guided Ph III study of enzastaurin + R-CHOP in high-risk diffuse large B-cell lymphoma (DLBCL)

First patient dosed in unique biomarker guided Ph III study of enzastaurin + R-CHOP in high-risk diffuse large B-cell lymphoma (DLBCL)

Submitted by admin on April 4, 2018 - 9:53am
Source: 
CP Wire
News Tags: 
biomarkers
enzastaurin
Denovo Therapeutics
DLBCL
R-CHOP
Headline: 
First patient dosed in unique biomarker guided Ph III study of enzastaurin + R-CHOP in high-risk diffuse large B-cell lymphoma (DLBCL)

Do Not Allow Advertisers to Use My Personal information